Didanosine - PharmaKB

Didanosine

Videx (didanosine) is a small molecule pharmaceutical. Didanosine was first approved as Videx on 1991-10-09. It is used to treat acquired immunodeficiency syndrome and HIV infections in the USA.

Download report

Favorite

BMS

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

Therapeutic Area	MeSH
infections	D007239
urogenital diseases	D000091642
immune system diseases	D007154

Trade Name

FDA

EMA

No data

Drug Products

FDA

EMA

New Drug Application (NDA)

Abbreviated New Drug Application (ANDA)

Didanosine

Tradename	Company	Number	Date	Products
VIDEX	Bristol Myers Squibb	N-020156 DISCN	1991-10-09	1 products, RLD
VIDEX	Bristol Myers Squibb	N-020154 DISCN	1991-10-09	5 products, RLD
VIDEX	Bristol Myers Squibb	N-020155 DISCN	1991-10-09	4 products
VIDEX EC	Bristol Myers Squibb	N-021183 DISCN	2000-10-31	4 products, RLD

Hide discontinued

Labels

FDA

EMA

Brand Name	Status	Last Update
didanosine	ANDA	2012-05-02

Indications

FDA

EMA

Indication	Ontology	MeSH	ICD-10
hiv infections	EFO_0000764	D015658	B20
acquired immunodeficiency syndrome	EFO_0000765	D000163	B20

Agency Specific

FDA

EMA

No data

Patent Expiration

No data

ATC Codes

J: Antiinfectives for systemic use

— J05: Antivirals for systemic use

— J05A: Direct acting antivirals

— J05AF: Nucleoside and nucleotide reverse transcriptase inhibitors

— J05AF02: Didanosine

HCPCS

Code	Description
S0137	Didanosine (ddi), 25 mg

Clinical

Clinical Trials

387 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Hiv infections	D015658	EFO_0000764	B20	39	53	29	15	28	160
Healthy volunteers/patients	—	—	—	88	—	—	1	1	90
Acquired immunodeficiency syndrome	D000163	EFO_0000765	B20	23	14	13	4	9	62
Infections	D007239	EFO_0000544	—	11	3	4	2	2	21
Hiv	D006678	—	O98.7	3	—	2	2	—	7
Lipodystrophy	D008060	—	E88.1	—	—	—	3	—	3
Cardiovascular diseases	D002318	EFO_0000319	I98	—	—	—	1	—	1
Hiv-associated lipodystrophy syndrome	D039682	EFO_1001348	—	—	—	—	1	—	1
Hemophilia a	D006467	EFO_0007267	D66	—	—	—	1	—	1
Hemophilia b	D002836	—	D67	—	—	—	1	—	1

Show 3 more

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Aids-related complex	D000386	EFO_0007137	B20	14	9	4	—	4	31
Neoplasms	D009369	—	C80	17	3	1	—	1	19
Communicable diseases	D003141	—	—	4	2	2	—	2	9
Tuberculosis	D014376	EFO_0000774	A15-A19	1	—	2	—	1	4
Gastrointestinal stromal tumors	D046152	EFO_0000505	C49.A	—	—	1	—	—	1

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Non-small-cell lung carcinoma	D002289	—	—	5	4	—	—	—	6
Colorectal neoplasms	D015179	—	—	4	2	—	—	—	5
Breast neoplasms	D001943	EFO_0003869	C50	2	2	—	—	—	3
Fibrosis	D005355	—	—	3	1	—	—	—	3
Myeloid leukemia acute	D015470	—	C92.0	2	2	—	—	—	2
Melanoma	D008545	—	—	2	1	—	—	—	2
Prostatic neoplasms	D011471	—	C61	1	1	—	—	—	2
Kaposi sarcoma	D012514	—	C46	1	1	—	—	—	2
Carcinoma	D002277	—	C80.0	2	1	—	—	—	2
Non-hodgkin lymphoma	D008228	—	C85.9	1	1	—	—	—	2

Show 25 more

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Drug interactions	D004347	—	—	20	—	—	—	4	24
Type 2 diabetes mellitus	D003924	EFO_0001360	E11	8	—	—	—	—	8
Pharmacokinetics	D010599	—	—	5	—	—	—	—	5
Malaria	D008288	EFO_0001068	B54	4	—	—	—	—	4
Atopic dermatitis	D003876	EFO_0000274	L20	4	—	—	—	—	4
Non-alcoholic fatty liver disease	D065626	EFO_0003095	K75.81	4	—	—	—	—	4
Dermatitis	D003872	—	L30.9	3	—	—	—	—	3
Hepatitis c	D006526	—	B19.2	2	—	—	—	1	3
Sarcoma	D012509	—	—	3	—	—	—	—	3
Diabetes mellitus	D003920	EFO_0000400	E08-E13	3	—	—	—	—	3

Show 70 more

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Hepatitis b	D006509	—	—	—	—	—	—	1	1
Hepatitis	D006505	—	K75.9	—	—	—	—	1	1
Hepatitis a	D006506	EFO_0007305	B15	—	—	—	—	1	1
Osteoarthritis	D010003	EFO_0002506	M15-M19	—	—	—	—	1	1
Blood coagulation disorders	D001778	EFO_0009314	D68.9	—	—	—	—	1	1
Hemostatic disorders	D020141	—	—	—	—	—	—	1	1
Heart failure	D006333	EFO_0003144	I50	—	—	—	—	1	1
Drug-related side effects and adverse reactions	D064420	—	T88.7	—	—	—	—	1	1
Irritable bowel syndrome	D043183	EFO_0000555	K58	—	—	—	—	1	1
Syndrome	D013577	—	—	—	—	—	—	1	1

Show 1 more

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Didanosine
INN	didanosine
Description	Didanosine is a purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen. An antiviral drug, it is used as a medication to treat HIV/AIDS. It has a role as an antimetabolite, a HIV-1 reverse transcriptase inhibitor, an antiviral drug, an EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor and a geroprotector.
Classification	Small molecule
Drug class	—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	O=c1[nH]cnc2c1ncn2[C@H]1CC[C@@H](CO)O1